adding therapeutic value

Photo_Michel_Souchet_2Espacement_President_HomepageHarmonic Pharma has developed a unique «pharmacological rediscovery ©» know-how based on polypharmacology to characterize new uses of safe drugs. Our approach allows an accelerated pre-clinical investigation in the newly identified indication while advancing drug candidates to a de-risked clinical development sooner.

Oncology is one of the major priorities of the company.

Michel Souchet, PhD – CEO

about polypharmacology

new_polypharmacology_9

about
harmonic pharma

Harmonic Pharma is the very first company developing and applying the polypharmacology paradigm to strategic therapeutic areas such as oncology. The company’s know-how derives from a breakthrough innovation  allowing to revisit safe drugs and drug candidates.

About us

pipeline

Harmonic Pharma’s pipeline comprises a selection of drugs with a known safety profile that can be evaluated rapidly in phase IIb, once efficacy in the novel selected indication is demonstrated.

Read more

major-achievements

latest
news

Biofit 2017
20 October 2017

Our chief scientific officer, Arnaud Sinan Karaboga, will give a presentation at the 14th Meet & Match event November 27 in Strasbourg. The topic of the day is « Strategies for drug discovery : Simulation – Screening – Repurposing » so be sure to be there !

Harmonica Pharma will also attend the 6th edition of BioFIT, the leading partnering event in Europe for technology transfer the 28th and 29th November.

View all news

Strategic partnering

Investment key factors:

  • Highly innovative technology for revisiting drugs allowing a robust transition from a novel mechanism of action to drug candidates
  • Team members with complementary and experienced backgrounds
  • Reducing time to clinical trial
  • Strong IP positions
  • Partnering with experts institutions in oncology

join us